ARVN News and Press, Arvinas Inc. From 08/05/19

Arvinas (NASDAQ: ARVN ): Q2 GAAP EPS of -$0.55 misses by $0.14 . Revenue of $4.01M (+17.9% Y/Y) beats by $0.32M . Press Release More news on: Arvinas, Inc., Earnings news and commentary, Healthcare stocks news,

NEW HAVEN, Conn., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter of 2019 and provided a corporate update. “We ...

NEW HAVEN, Conn., July 29, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced today the appointment of Ronald Peck, M.D. to the newly created position of Chief Medical Officer (CMO). D...

NEW HAVEN, Conn., July 18, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced it will present preclinical data from its tau-targeted PROTAC® protein degrader program at the Alzhei...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

Gilead Sciences ( GILD ) announced a partnership with Nurix Therapeutics to develop potential drugs to treat cancer and other diseases. This is a good deal for the company, because it gets another partnership on board as it struggles to establish a solid pipeline. Gilead has been able to a...

The FDA has cleared Arvinas' (NASDAQ: ARVN ) IND application for ARV-471, an oral estrogen receptor (ER) PROTAC protein degrader, designed to selectively target ER for the treatment of patients with locally advanced or metastatic ER positive / HER2 negative breast cancer. ...

 - Initiation of Phase 1 Trial expected in the third quarter of 2019 - ARV-471 will be Arvinas’ second targeted PROTAC ® protein degrader to enter the clinic NEW HAVEN, Conn., June 25, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company ...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you ca...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...